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Adenocarcinomas of rectum and colon may be diﬀerent with regard to the cellular biological basis for cancer development. A
material of 246 rectal cancers removed surgically at Akershus University Hospital in the years 1992–2000 was investigated and
was compared to a material of 219 colon cancers operated on at Akershus University Hospital during the years 1988, 1990 and
1997–2000. There were highly signiﬁcant diﬀerences between the rectal and the colon cancers in the protein expression of cyclin
D1, cyclin D3, cyclin E, nuclear β-catenin, and c-Myc and in gene ampliﬁcation of cyclin A2, cyclin B1, cyclin D1, and cyclin E.
Gene ampliﬁcation and protein expression in the rectal cancers correlated signiﬁcantly for the cyclins B1, D3, and E. A statistically
signiﬁcant relation was observed between overexpression of cyclin A2 and local relapse of rectal carcinomas, as higher expression
of cyclin A2 was associated with lower local recurrence rate.
Copyright © 2009 Rolf Aamodt et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Despite the fact that adenocarcinomas of rectum and colon
have the same appearance both macroscopically and micro-
scopically, they may be diﬀerent with regard to the cellular
biological basis for cancer development. In a previous study,
we found a higher protein expression of nuclear β-catenin in
rectal cancers than in colon cancers [1], indicating biological
diﬀerences between rectal and colon adenocarcinomas. Since
β-catenin is involved in cell proliferation, it is important to
evaluate whether other genes, involved in cell cycle and cell
proliferation, may also be diﬀerentially expressed in these
two carcinomas.
Cyclins regulate cell cycle by binding to and activating
cyclin dependent kinases (CDKs). CDKs in turn phospho-
rylate other proteins. Stimulation from cyclins is mandatory
for cell cycle progression and cell division. Diﬀerent cyclins
act at diﬀerent stages of the cell cycle. Cyclin D1, D2, and D3
bind to CDK4 and CDK6. This allows the cell to enter the G1
phase [2]. The expression of cyclin D does not vary through
the cell cycle, in contrast to the expression of other cyclins
[3]. Cyclin E binds to CDK2 and lets the cell go from G1 to
S phase [4] .C y c l i nAa c t sa tt w od i ﬀerent steps during the
cell cycle. Firstly, it binds to CDK2 and is necessary during S
phase [5, 6]. Secondly, it binds to CDK1 and so permits the
cell to enter M phase [7]. Cyclin B binds to CDK1 and lets
the cell cycle progress through M phase [8, 9].
Abnormally located β-catenin plays its role in colorectal
tumorigenesis [10] by being part of the signaling cascade
of the Wnt pathway [11]. β-catenin acts in association
with adenomatous polyposis coli (APC) in tumorigenesis
[12, 13]. Mutations in either β-catenin or APC can distort
the normal tumor suppressive eﬀect of APC [13]. Somatic
mutations of the APC gene cause malfunctioning APC in
80% of colorectal cancers [10]. This malfunctioning APC
failstoreducethelevelofcytoplasmicβ-catenin[10,14].The2 Gastroenterology Research and Practice
Table 1: Primary antibodies used for immunohistochemistry.
Antibody Retrieval method Dilution Incubat time Host species Clone Vendor
Cyclin A2 Tris/EDTA, pH 9 1 : 150 32 min Mouse, monoclonal 6E6 Novocastra∗
Cyclin B1 Tris/EDTA, pH 9 1 : 40 30 min Mouse, monoclonal 7A9 Novocastra∗
Cyclin D1 Dako TRS, pH 6 1 : 50 30 min Rabbit, monoclonal SP4 Lab Vision†
Cyclin D3 Tris/EDTA, pH9 1 : 20 30 min Mouse, monoclonal DCS-22 Novocastra∗
Cyclin E Tris/EDTA, pH9 1 : 40 30 min Mouse, monoclonal 13A3 Novocastra∗
c-Myc Tris/EDTA, pH 9 1 : 50 30 min Mouse, monoclonal 9E11 Novocastra∗
β-catenin Tris/EDTA, pH 9 1 : 300 30 min Mouse, monoclonal 17C2 Novocastra∗
∗Novocastra, Newcastle, UK
†Lab Vision, Fremont, CA.
resulting increased level of cytoplasmic β-catenin induces
transcription of cyclin D1 and c-Myc through the TCF/LEF
pathway [10].
c-Myc binds to speciﬁc binding sites on DNA, there
regulating the transcription of other genes [15]. The protein
expression of c-Myc is elevated in colon cancers [16, 17]. c-
Myc is one of the most often deregulated oncoproteins in
cancer [15, 18].
Overexpression of cyclins is associated with poor patient
prognosis in colorectal cancer patients. One of the mech-
anisms behind overexpression is gene ampliﬁcation of the
cyclins’ genes at the DNA level. However, the overexpression
may also be caused at the posttranslational level. The
prognostic value of cyclin overexpression may be diﬀerent
whether overexpression is caused by gene ampliﬁcation or
by impaired degradation. This may especially be important
regarding cyclin A.
The clinical outcome of rectal cancer patients has histor-
ically been diﬀerent from that of colon cancer patients. The
most important diﬀerence has been the frequency of local
relapse before irradiation was introduced as a routine preop-
erative treatment for a large proportion of the rectal adeno-
carcinomas. Local relapse is a result of “local expansion” of
tumor cells, where cyclins may play an important role.
The aim of the present study was to evaluate whether
there are diﬀerences in expression and gene ampliﬁcation
of cyclins in rectal compared to colon adenocarcinomas. We
also wanted to relate our laboratory results on rectal cancers
to patient prognosis.
2.MaterialsandMethods
2.1. Patient Materials. All available tumor samples from a
consecutiveseriesof274paraﬃn-embeddedrectaladenocar-
cinomas removed surgically at Akershus University Hospital
in the years 1992–2000 were scrutinized for inclusion into
the survey. These surgical treatments were all primary
operations. We decided to include solely tumors at a level of
15 centimeters (5.9 inches) or less from the anal verge (i.e.,
the outer border of the anus) (246 patients). This level is
withintheclinicallycommonlyusedandsomewhatarbitrary
range of 15 to 18 centimeters, used to deﬁne the border
between rectum and colon. We wanted a restrictive border
in order to avoid unintentional inclusion of sigmoid tumors.
This material of rectal carcinomas was compared to a
material by Bondi et al. of 219 colon carcinomas operated on
at Akershus University Hospital during the years 1988, 1990,
and 1997–2000 [19].
Cancer speciﬁc death was registered only if metastasis
was diagnosed, and the cancer disease was stated as the cause
of death in the certiﬁcate of death.
Out of 246 patients 25 had a local recurrence of their
rectal cancer. Mean time from primary operation was
performed till local recurrence occurred, was 2.3 years.
Minimum time was ﬁve months, maximum time 6.0 years.
Mean observation time for patients with no local recurrence
observed, was 6.2 years. Minimum observation time was 0
years (two patients), while maximum observation time was
14.5 years.
2.2. Immunohistochemistry. Serial sections (3-4 microme-
ters) from formalin ﬁxed, paraﬃn wax embedded archive
t u m o rt i s s u ew e r ea p p l i e dt oc o a t e ds l i d e sb e f o r ei m m u n o -
histochemical staining. After antigen retrieval by microwav-
ing (20 minutes at 100◦C), immunostaining with antibodies
to cyclins A2, B1, D1, D3, and E, in addition to c-Myc and
β-catenin, was performed, according to the operation proto-
cols. Dako Autostainer (Dako Corporation, Carpinteria, CA)
was used for cyclins B1, D1, E, c-Myc, and β-catenin, while
staining for cyclins A and D3 was performed in Ventana ES
automated slide stainer (Ventana Medical Systems, Tucson,
AZ). The details of each antibody used are shown in
Table 1. The antibodies were visualized for light microscopy
with Envision Plus-System and diaminobenzidine (DAB),
and with Detection Kit Ventana iView DAB, respectively.
Counter staining was done with Hagen’s haematoxylin for
visualization of tissue structures. Positive control was a
test block with normal colon mucosa and multiple colon
adenocarcinomas with diverse diﬀerentiation.
The percentage of positive nuclei was counted semiquan-
titatively by applying four grades of immunopositivity, 3, 2,
1, and 0. We intended to compare our ﬁndings on rectal
cancers to ﬁndings previously recorded on colon cancers by
Bondi et al. [19, 20]. We therefore chose the same cut-oﬀs
for the immunohistochemical markers as previously applied
by them. When 60% or more of the tumor cell nuclei were
stained, the tumor was graded as grade 3. Staining of 30% up
to 60% of the nuclei was classiﬁed as grade 2. When nuclearGastroenterology Research and Practice 3
Figure 1: Representative example of immunopositivity grade 3 for
cyclin A (original magniﬁcation ×200).
staining was less than 30%, the score was grade 1. No nuclear
immunostaining at all qualiﬁed for grade 0. Only clearly
nuclear staining was recorded as positive, except in cyclin
B1, where also cytoplasmic staining qualiﬁed for positivity
[21]. Examples of immunostaining are shown in Figures 1,
2, 3,a n d4. Almost all slides contained normal adjacent
mucosa in addition to the cancer. The normal mucosa served
as an internal control, and the level of cut-oﬀ was set at
the staining level of normal mucosa. The slides were judged
independently by three investigators (RAa, IRKB, and JB). At
least100,usuallymorethan1000cellswereexaminedineach
slide.
2.3. Gene Ampliﬁcation Analyses. Genomic DNA was
extracted from 30μm section of formalin ﬁxed, paraﬃn
embedded (FFPE) tumor tissue, in a GenoMTM-48 Robotic
Workstation (GenoVision, Oslo, Norway), as described
by the manufacturer (GenoMTM-48, Qiagen protocol:
Isolation of genomic DNA from paraﬃn-embedded sections
using the MagAttract DNA Mini M48 Kit, December
2003, GenoVision). The DNA concentration was measured
using NanoDrop ND-1000 Spectrophotometer (NanoDrop
Technologies Wilmington, Delaware, USA). All samples
consisted of >75% tumor tissue conﬁrmed by light
microscopy of a haematoxylin and eosin stained slide made
from the adjacent tissue of the paraﬃn block.
Todeterminegeneampliﬁcationordeletionweusedreal-
time PCR on an ABI Prism 7900HT Sequences detection
system (Applied Biosystems, Foster City, CA, USA) with
software program SDS2.3. Primers and probes for cyclin
B1, D1, D3, and E have previously been described by
Bondi et al. [20]. Primers and probes for housekeeping
gene human serum albumin (HSA) (assay Hs99999922 s1)
were commercially designed by Applied Biosystems. Aagaard
Sørby et al. designed primers and probes for cyclin A2
(personal communication). Primers and probe assays for
cyclin A2 were purchased from Applied Biosystems. The
order number was 2400949 in the Custom TaqMan Gene
Expression Assay Service. The detailed information about
primers and probes used for diﬀerent cyclins is shown in
Table 2.
Figure 2: Representative example of immunopositivity grade 3 for
cyclin D1 (original magniﬁcation ×200).
Figure 3: Representative example of immunopositivity grade 3 for
cyclin E (original magniﬁcation ×200).
Figure 4: Representative example of immunopositivity grade 3 for
β-catenin (original magniﬁcation ×200).
We performed the PCR ampliﬁcation of cyclins using a
96-well tray with a 20-μL ﬁnal reaction mixture containing
10μL TaqMan Universal PCR Master Mix, NoAmpErase
UNG (2x), 1μL 20x Assay Mix,4μLd H 2O, and 5 μLD N A4 Gastroenterology Research and Practice
Table 2: Primer and probe sequences for cyclins used in real time quantitative polymerase chain reaction.
Gene Primer sequence (5 –3 ) Hybridisation probe sequence (5 –3 )
CCNA2
Forward GCCACAGTAGGAGTTCTCCCATAT FAM-CCCCGCCAACACTG-NFQ
Reverse CAGACCGGCAGCATACACA
CCNB1
Forward CCCTGCTGCAACCTCCAA FAM-CCCGGACTGAGGCCAAGAACAGC-TAMRA
Reverse TGTTCACTGACTTTGTTACCAATGTC
CCND1
Forward CCGTCCATGCGGAAGATC FAM-CCTCCAGCATCCAGGTGGCGA-TAMRA
Reverse AACAAGTTGCAGGGAAGTCTTAAGA
CCND3
Forward CTGTCTCTCCCCGCCAGTT FAM-CACCCCCGACACGTATTGTCTCCC-TAMRA
Reverse CTGATATCTCAAGCTTTCCTTTTCCT
CCNE
Forward CCCCGCTGCCTGTACTGA FAM-TCAGTGCCGACTCTGCCACATGG-TAMRA
Reverse AGCATGGAGTAAGAGACCTGGAA
(5ng/μL). For the rest of the cyclins, the PCR mix consisted
of 2μL DNA (2–7.5ng/μL), 2x TaqMan Universal PCR
MasterMixfromAppliedBiosystems,600nMofforwardand
reverse primer and 80nM probes for the genes cyclin B1, D1,
D3, and E according to Applied Biosystems manufacturer’s
instructions. The TaqMan gene expression assays for cyclin
A2 and HSA contained 900nM of forward and reverse
primer and 250nM FAM dye-labeled TaqMan probe. We
addedwatertothetotalreactionvolumeof20μL.Allsamples
were run as triplicates. Default thermal cycling conditions
were used in the PCR (Applied Biosystems).
To determinate the relative gene copy number of DNA of
the cyclin genes we normalized the results to the level of HSA
for each sample. This determination was done by means of
the 2−ΔΔCt-method [22]. Threshold cycle number, Ct, for the
real-time quantiﬁcation was deﬁned to be in the exponential
phase of the PCR ampliﬁcation. The calibrator used in the
real-time PCR experiments was the mean of Ct-values of
seven rectal cancer patients’ normal rectal mucosal tissue.
2.4. Statistics. Statistical analyses were performed by SPSS
version 14.0 running on Windows XP. Fisher’s exact test,
Kaplan-Meier log rank test, correlation analysis, binary
logistic regression analysis, and Cox regression analysis were
performed. We made test plots for proportional hazards
for the Cox analyses and found them satisfactory. Pearson
correlation was used when comparing protein expression
to gene ampliﬁcation. We chose an alpha level of statistical
signiﬁcance of P<. 05.
3. Results
The clinico-histopathological characteristics of the patients
are shown in Table 3.
There were highly signiﬁcant diﬀerences between the
rectal and the colon cancers in the protein expression
of cyclin D1, cyclin D3, cyclin E, nuclear β-catenin, and
c-Myc (Table 4), even when adjusted for Dukes’ stage,
diﬀerentiation grade, gender, and age of patient at the time
of surgery.
There were also signiﬁcant diﬀerences between rectal
and colon cancers in gene ampliﬁcation of all cyclins except
cyclin D3 (Table 5), even when adjusted for gender, tumor
diﬀerentiation grade, Dukes’ tumor stage and age at surgery.
When gene ampliﬁcation level of cyclins was evaluated
in rectal adenocarcinomas, we observed the highest ampli-
ﬁcation level in the cyclin E gene, showing ampliﬁcation in
the largest proportion, 18%, of the samples. Cyclin A2 and
cyclin D1 were ampliﬁed in 9% and 8%, respectively. The
ampliﬁcation proportion for cyclin D3 and cyclin B1 was
only 2% and 1%, respectively (Table 6). The cut-oﬀ level was
set to two.
When correlation between protein expression and gene
ampliﬁcation was analyzed, we observed a signiﬁcant corre-
lation between protein expression and gene ampliﬁcation of
cyclin B1, cyclin D3, and cyclin E, although the correlation
coeﬃcient was rather low (Table 7). No signiﬁcant correla-
tion existed for cyclin A2 or cyclin D1 (Table 7).
We examined associations between protein expression of
diﬀerent cyclins, as well as c-Myc and β-catenin, and patient
prognosis in rectal cancer patients. In univariate analyses
with Fisher’s exact test (Table 8) there was a signiﬁcant
relation between occurrence of local recurrence and cyclin
A protein expression (P = .0056 after Bonferroni correc-
tion). When we examined time from surgery till clinical
manifestations in univariate analyses with Kaplan-Meier Log
Rank Test (Table 9), there was a signiﬁcant relation between
local recurrence and cyclin A protein expression (P = .0062
afterBonferronicorrection).WeperformedmultivariateCox
regression analyses that included all seven examined proteins
in addition to patient gender, tumor diﬀerentiation grade,
Dukes’ tumor stage, patient age at surgery, and time fromGastroenterology Research and Practice 5
Table 3: Rectal and colon cancers’ characteristics, numbers (percentages in parentheses, (%)).
Rectal cancers
Gender Males: 150 (61) Females: 96 (39)
Age at operation Lowest: 16 Mean: 66 Highest: 90
Dukes’ stage A: 45 (18) B: 100 (41) C: 69 (28) D: 30 (12)
T stage T1: 8 (3) T2: 46 (19) T3: 187 (76) T4: 5 (2)
N stage N0: 154 (63) N1: 63 (26) N2: 29 (12)
M stage M0: 214 (87) M1: 30 (12)
Tumor diﬀerentiation Poor: 7 (3) Moderate: 235 (96) High: 2 (1)
Colon cancers
Gender Males: 105 (48) Females: 114 (52)
Age at operation Lowest: 40 Mean: 70 Highest: 93
Dukes’ stage A: 10 (5) B: 105 (48) C: 57 (26) D: 47 (22)
T stage T1: 4 (2) T2: 27 (12) T3: 173 (79) T4: 14 (6)
N stage N0: 137 (63) N1: 65 (30) N2: 15 (7)
M stage M0: 169 (77) M1: 47 (22)
Tumor diﬀerentiation Poor: 23 (11) Moderate: 184 (84) High: 11 (5)
Table 4: Protein expression. Variables that showed a signiﬁcant diﬀerence between rectal cancers and colon cancers (results of binary logistic
regression analysis on 400 patients).
Variable Largest in
rectum or colon
P-value OR 95% CI for OR
Cyclin D1 Rectum P<. 001 9.933 [4.355; 22.654]
Cyclin D3 Colon P<. 001 0.239 [0.109; 0.524]
Cyclin E Rectum P<. 001 3.282 [1.834; 5.872]
Nuclear β-catenin Rectum P<. 001 38.514 [14.414; 102.906]
c-Myc Colon P = .001 0.253 [0.115; 0.558]
surgery till clinical event. There was a signiﬁcant association
between cyclin A2 expression and reduced local relapse (P =
.001, HR = 0.410, 95% CI for HR [0.247;0.682]). Expression
ofc-Mycwasassociated with reducedcancer speciﬁcsurvival
in rectal cancer (P = .003, HR = 3.714, 95% CI for
HR [1.568;8.797], while overexpression of c-Myc in colon
adenocarcinomas not treated with adjuvant chemotherapy
was associated with higher cancer speciﬁc survival (P = .028,
HR = 0.353, 95% CI for HR [0.140;0.893]).
There was no signiﬁcant relationship between gene
ampliﬁcation level in the rectal cancers and local recurrence
of the cancer, distant metastases, cancer speciﬁc death, or
lymph node metastases.
4. Discussion
Inthepresentstudy,wehave,fortheﬁrsttime,demonstrated
that both protein expression and gene ampliﬁcation of
several proteins important for cell cycle progression, are
diﬀerent in rectal adenocarcinomas compared to colon
adenocarcinomas, even when adjusted for Dukes’ stage,
tumor diﬀerentiation grade, and age of patient at the time
of surgery. These results indicate diﬀerent gene expression
patterns and biological mechanisms between colon and
rectal adenocarcinomas. The diﬀerences between these two
entities observed in the present study can be correlated
to clinical diﬀerences between the two diseases in clinical
practice.
A statistically signiﬁcant correlation was also observed
between overexpression of cyclin A2 and local relapse of
rectal carcinomas. Higher expression of cyclin A2 was
associated with lower local recurrence rate. It is interesting
to observe that the eﬀect of cyclin A2 overexpression in
rectal adenocarcinomas is diﬀerent from its eﬀect in most
other cancers. Higher cyclin A2 expression may lead to
poor patient prognosis for several other tumors, among
them breast cancer [23–49]. So far, only in anal cancer [50]
and probably in colon cancer cyclin A overexpression has
indicated better clinical outcome.
Reports on the impact of cyclin A protein expression
on clinical outcome of colon cancers diverge. Most of these
studies ﬁnd an unfavorable clinical eﬀect in patients with
high cyclin A protein expression in the tumor tissue. In
two materials of mainly colon cancers and to a lesser
extent rectal cancers regarded as a whole, cyclin A protein6 Gastroenterology Research and Practice
Table 5:Geneampliﬁcation.Variablesthatshowedasigniﬁcantdiﬀerencebetweenrectalcancersandcoloncancers(resultsofbinarylogistic
regression analysis on 403 patients).
Variable H i g h e s ti nr e c t u mo r
colon
P-value OR 95% CI for OR
Cyclin A2
ampliﬁcation Rectum P<. 001 23.286 [7.316; 74.119]
Cyclin B1
ampliﬁcation Rectum P = .008 8.056 [1.718; 37.781]
Cyclin D1
ampliﬁcation Colon P<. 001 0.005 [0.001; 0.017]
Cyclin E
ampliﬁcation Rectum P<. 001 5.248 [2.417; 11.395]
Age at surgery Colon P = .017 0.955 [0.919; 0.992]
Table 6: Ampliﬁcation of cyclin genes of the rectal cancers.
Gene N (total) Ampliﬁcation level∗
<0.5 0.5–1.9 2.0–4.9 ≥5
Cyclin A2 237 9 206 21 1
Cyclin B1 236 4 229 3 0
Cyclin D1 236 5 212 19 0
Cyclin D3 234 22 207 5 0
Cyclin E 235 2 191 40 2
∗N-fold diﬀerence from the normal controls. Ampliﬁcation was measured
by real-time quantitative polymerase chain reaction, and levels were
determined by the comparative Ct method (2−ΔΔCt method).
overexpression was associated with impaired overall survival
[51, 52]. However, it is hard to decipher exactly how large
proportion of one of these materials [52] was colon cancers.
Anotherproblemmaybe that overallsurvivalmaynot reﬂect
the cancer speciﬁc survival. In another material of colorectal
patients the conclusion was the same [53]. These three
reportswereoncolorectalpatients,thatis,amixtureofcolon
and rectal cancers. If the clinical eﬀects of high cyclin A diﬀer
between colon and rectal cancers, the interpretation of these
three studies might be somewhat diﬃcult. In a material of
solely colon cancers high cyclin A indicated better survival
[20], especially in Dukes’ stage D.
The expression of c-Myc was also analyzed in this study
and compared to the expression of the same protein in colon
adenocarcinomas. c-Myc stimulates cell growth [54]. Con-
trolofthecellcycleisusuallylostiftheexpressionofc-Mycis
deregulated [55]. Higher c-Myc was associated with reduced
cancer speciﬁc survival in rectal cancer patients, while in
colon cancer patients without adjuvant chemotherapy, high
c-Myc expression was associated with better prognosis.
To evaluate whether overexpression of cyclins detected
in the present study was a result of ampliﬁcation at the
DNA level, gene ampliﬁcation analyses were performed
for all cyclins included in the study. Gene ampliﬁcation
analyses on the rectal cancers revealed a signiﬁcant but
fairlylowcorrelationbetweengeneampliﬁcationandprotein
expression only for the cyclins B1, D3, and E. No correlation
between gene ampliﬁcation and protein expression was
observed for cyclin A2. Earlier studies have showed that
protein overexpression of cyclins can occur without gene
ampliﬁcation [20, 56–58]. Our results indicate that gene
ampliﬁcation contributes to the variation seen in protein
expression of cyclins in rectal cancer. But it does not oﬀer
a major explanation to this. Therefore, protein expression of
cyclins in rectal cancer has to be regulated mainly by other
mechanisms.
It is of importance, especially regarding cyclin A2, to
explore the mechanism behind overexpression. It has been
shown that overexpression of cyclin A in the S-phase of
the cell cycle is associated with poor prognosis, while
overexpression of cyclin A in the M-phase of the cell cycle
is associated with better prognosis. It is reason to believe that
overexpression caused by reduced degradation of a protein
may result in accumulation of this protein also in the M-
phase, while overexpression caused by high production, but
intact degradation process may act mostly at the S-phase of
the cell cycle. It is possible to speculate that overexpression
of cyclin A2 caused by gene ampliﬁcation may act mainly
in the S-phase of the cell cycle. Thus, in rectal cancer, we
believe overexpression of cyclin A2 protein is caused mainly
by impaired degradation of the protein. This causes a high
cyclin A2 concentration in M-phase in addition to in S-
phase, leading to better clinical outcome.
Most colon cancers, especially those distal to the splenic
ﬂexure, evolve by the cromosomal instability (CIN) pathway.
Fifteen percent of colon cancers evolve by the microsatellite
instability (MSI) pathway. The MSI cancers are typically
located proximal to the splenic ﬂexure. In sporadic cancers,
MSI is mainly caused by epigenetic silencing. There are
indications of rectal cancers seldom having MSI [59]a n d
often having CIN [60]. Other investigations only partially
support these results [61, 62]. However, although their
approaches diﬀer from ours, except on β-catenin [62],
individual results in these investigations indicate diﬀerences
between rectal and colon cancers. This is in accordance with
our ﬁndings.Gastroenterology Research and Practice 7
Table 7: Correlation between protein expression and gene ampliﬁcation of cyclins in rectal cancers.
Cyclin Pearson correlation
coeﬃcient
R squared P-value Number of rectal
cancers examined
Cyclin A2 0.101 0,010201 P = .124 232
Cyclin B1 0.156 0,024336 P = .017 233
Cyclin D1 −0.019 0,000361 P = .772 233
Cyclin D3 0.295 0,087025 P<. 001 226
Cyclin E 0.188 0,035344 P = .004 232
Table 8: Cross table with Fisher’s exact test. P-values without Bonferroni correction.
Protein Local
recurrence
Distant
metastases
Lymph node
metastases
Cancer speciﬁc
death
Cyclin A 0.0008 0.299 0.286 0.141
Cyclin B 0.982 0.377 0.270 0.870
Cyclin D1 0.035 0.240 0.214 0.287
Cyclin D3 0.688 1.000 0.347 0.875
Cyclin E 0.481 0.522 0.075 0.088
Nuclear β-catenin 0.718 0.187 0.248 0.330
c-Myc 0.715 0.285 0.080 0.057
Table 9: Kaplan-Meier Log Rank Test. P-values without Bonferroni
correction.
Protein Local
recurrence
Distant
metastases
Cancer speciﬁc
death
Cyclin A 0.000889 0.325 0.311
Cyclin B 0.854 0.425 0.692
Cyclin D1 0.055 0.295 0.322
Cyclin D3 0.575 0.964 0.734
Cyclin E 0.409 0.515 0.123
Nuclear
β-catenin 0.528 0.172 0.274
c-Myc 0.281 0.269 0.082
5. Conclusions
In conclusion, only a few surveys exist on the biological dif-
ferences between colon and rectal adenocarcinomas, despite
the fact that colon and rectal cancer patients may have
diﬀerent clinical prognosis. The present study is one of the
ﬁrststudieswhereproteinsimportantforcellcycleregulation
are examined separately in colon and rectal adenocarcino-
mas. The results show biological diﬀerences between rectal
and colon adenocarcinomas. The study demonstrates the
necessity for examining these two disease entities separately.
These biological diﬀerences may have signiﬁcant impact
when planning therapy for colorectal cancer patients.
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